Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy Volunteers (MB)

AstraZeneca

Status and phase: Terminated; Phase 1

Conditions: Alzheimer's Disease

Treatments: Drug: AZD3480

Study type: Interventional

Funder types: Industry

Identifiers

NCT00777361

D3690C00017

EudraCT No.: 2007-005903-16

Details and patient eligibility

About

This study is being performed in order to learn more about a new drug (possible as treatment for people with Alzheimer's Disease and other conditions with cognitive dysfunction (memory and attention problems)) and how it is handled by the body by giving the drug to healthy volunteers with different genotypes.

Enrollment: 9 patients

Sex: Male

Ages: 35 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Physically healthy volunteers
• Participation in a previous study for genotyping for identification to be extensive, intermediate or poor metaboliser (CYP2D6 enzyme)

Exclusion criteria

• History of clinically significant diseases or illness.
• Ues of any prescribed or non-prescribed medications from 2 weeks prior to first treatment day except for paracetamol and OTC adrenergic nasal spray.

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

9 participants in 2 patient groups

AZD3480 iv

Experimental group

Description:

Single iv infusion AZD3480

Treatment:

Drug: AZD3480

Drug: AZD3480

Oral [14C] AZD3480

Experimental group

Description:

Single oral dose \[14C\]AZD3480

Treatment:

Drug: AZD3480

Drug: AZD3480